Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD4 | P21917 | 5/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770279 | 0.94 | KMT2A (0.56) | KMT2ADRD2DRD4HRH3L3MBTL3 | |
| SCHEMBL3767807 | 0.90 | DRD2 (0.56) | KMT2ADRD2DRD4HRH3L3MBTL3 | |
| SCHEMBL3774288 | 0.87 | KMT2A (0.53) | KMT2ADRD2DRD4HRH3 | |
| SCHEMBL3771229 | 0.86 | KMT2A (0.50) | KMT2ADRD2DRD4HRH3SLC6A5 | |
| SCHEMBL3774347 | 0.85 | SLC6A5 (0.55) | KMT2ADRD2DRD4HRH3L3MBTL3 | |
| SCHEMBL3774004 | 0.85 | DRD2 (0.51) | KMT2ADRD2DRD4HRH3 | |
| SCHEMBL3770062 | 0.85 | ALDH1A1 (0.57) | KMT2AHRH3SLC6A5 | |
| SCHEMBL3776073 | 0.85 | KMT2A (0.70) | KMT2ADRD4HRH3SLC6A5 | |
| SCHEMBL3769105 | 0.85 | KMT2A (0.51) | KMT2ADRD2DRD4HRH3L3MBTL3 | |
| SCHEMBL3760993 | 0.84 | KMT2A (0.58) | KMT2ADRD2DRD4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | KMT2A 242/4885DRD2 473/4885DRD4 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.